Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
62.65
+0.78 (1.26%)
At close: Dec 10, 2025, 4:00 PM EST
62.86
+0.21 (0.34%)
After-hours: Dec 10, 2025, 7:54 PM EST
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Halozyme Therapeutics stock have a consensus rating of "Buy" and an average price target of $73.33, which forecasts a 17.05% increase in the stock price over the next year. The lowest target is $53 and the highest is $92.
Price Target: $73.33 (+17.05%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 3 | 3 | 3 | 3 |
| Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Hold | 5 | 3 | 3 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +43.66% | Nov 28, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $54 → $56 | Hold | Maintains | $54 → $56 | -10.61% | Nov 18, 2025 |
| Citizens | Citizens | Buy Maintains $91 → $92 | Buy | Maintains | $91 → $92 | +46.85% | Nov 4, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $63 → $65 | Hold | Maintains | $63 → $65 | +3.75% | Oct 27, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $80 → $79 | Buy | Maintains | $80 → $79 | +26.10% | Oct 20, 2025 |
Financial Forecast
Revenue This Year
1.37B
from 1.02B
Increased by 34.83%
Revenue Next Year
1.71B
from 1.37B
Increased by 24.84%
EPS This Year
6.40
from 3.43
Increased by 86.57%
EPS Next Year
8.29
from 6.40
Increased by 29.58%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.4B | 1.9B | ||||
| Avg | 1.4B | 1.7B | ||||
| Low | 1.3B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 40.9% | 37.0% | ||||
| Avg | 34.8% | 24.8% | ||||
| Low | 27.3% | 13.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 6.71 | 9.47 | ||||
| Avg | 6.40 | 8.29 | ||||
| Low | 6.06 | 7.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 95.6% | 48.0% | ||||
| Avg | 86.6% | 29.6% | ||||
| Low | 76.6% | 10.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.